Cite

HARVARD Citation

    Drilon, A. et al. (2020). Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet oncology. 21 (2), pp. 261-270. [Online]. 
  
Back to record